Introduction: This study aimed to investigate the association between polymorphisms in
fibrinogen genes and bleeding risk in patients receiving direct oral anticoagulants (DOACs) …

Objectives: The purpose of our study is to investigate the effects of apolipoprotein B (APOB)
and APOE gene polymorphisms on bleeding complications in patients receiving direct oral …

The purpose of this study was to identify the renin–angiotensin system (RAS)-related genetic
factors associated with bleeding and develop the bleeding risk scoring system in patients …

Aims: The present study focussed on deriving and validating a 'genetic bleeding risk
score'(GBRS) based on genetic and non-genetic factors associated with bleeding in patients …

Introduction: Bleeding is one of the most undesirable complications of direct oral
anticoagulants (DOACs). While the ryanodine receptor (RYR2) has been related to cardiac …

BACKGROUND AND OBJECTIVES: There is very considerable inter-individual variability in
warfarin dosages necessary to achieve target therapeutic anticoagulation. The variability is …

Background/Objectives: Direct oral anticoagulants (DOACs) are first-line medications for
stroke prevention in non-valvular atrial fibrillation (AF). However, variability in drug response …

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking
rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large …

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking
rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large …

This meta‐analysis aimed to investigate the effect of the genotype on the pharmacokinetics
and bleeding events of direct oral anticoagulants (DOACs) and comprehensively searched …